Skip to main content
Premium Trial:

Request an Annual Quote

Xantos to Use Atugen s RNAi Compounds for Cancer Target Validation

NEW YORK, April 15 (GenomeWeb News) - Xantos Biomedicine today announced an agreement to use Atugen's atuRNAi short interfering RNAi compounds to validate an angiogenic target in animal studies.

 

Atugen said that its atuRNAi gene-silencing approach has already been "successfully applied to validate and modulate disease targets in liver diseases and several animal models for cancer."

 

Financial details of the collaboration were not disclosed.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.